{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:26:12Z","timestamp":1790047572446,"version":"4.0.1"},"reference-count":193,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI117970"],"award-info":[{"award-number":["P30-AI117970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI124722"],"award-info":[{"award-number":["R01-AI124722"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI147845"],"award-info":[{"award-number":["R01-AI147845"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21\/R33-AI116212"],"award-info":[{"award-number":["R21\/R33-AI116212"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1-AI126617"],"award-info":[{"award-number":["UM1-AI126617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02450","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T08:42:35Z","timestamp":1571128955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists"],"prefix":"10.3389","volume":"10","author":[{"given":"Amanda B.","family":"Macedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Novis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1128\/JVI.78.3.1160-1168.2004","article-title":"T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis","volume":"78","author":"Brenchley","year":"2004","journal-title":"J Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/jac\/dkv084","article-title":"Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission","volume":"70","author":"Cheret","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1097\/QAD.0b013e32833b61ba","article-title":"Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection","volume":"24","author":"Hocqueloux","year":"2010","journal-title":"AIDS."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study","volume":"9","author":"Saez-Cirion","year":"2013","journal-title":"PLoS Pathog."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1097\/QAD.0000000000001195","article-title":"Polyfunctional HIV-specific T cells in Post-Treatment Controllers","volume":"30","author":"Samri","year":"2016","journal-title":"AIDS."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e9390","DOI":"10.1371\/journal.pone.0009390","article-title":"Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection","volume":"5","author":"Archin","year":"2010","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","article-title":"Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells","volume":"22","author":"Archin","year":"2008","journal-title":"AIDS."},{"key":"B15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: a proof-of-concept study","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1468-1293.2011.00975.x","article-title":"Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study","volume":"13","author":"Routy","year":"2012","journal-title":"HIV Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0b013e3282fd6ddc","article-title":"Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir","volume":"22","author":"Sagot-Lerolle","year":"2008","journal-title":"AIDS."},{"key":"B18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1086\/511823","article-title":"Stability of the latent reservoir for HIV-1 in patients receiving valproic acid","volume":"195","author":"Siliciano","year":"2007","journal-title":"J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat","volume":"210","author":"Archin","year":"2014","journal-title":"J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PLoS Pathog."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"Sogaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Gutierrez","year":"2016","journal-title":"AIDS."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV."},{"key":"B26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cid\/cit813","article-title":"A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy","volume":"58","author":"Spivak","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4161\/hv.23800","article-title":"Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation","volume":"9","author":"Rasmussen","year":"2013","journal-title":"Hum Vaccin Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molmed.2015.11.004","article-title":"HIV-1 eradication: early trials (and Tribulations)","volume":"22","author":"Spivak","year":"2016","journal-title":"Trends Mol Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: an update","volume":"10","author":"Van Lint","year":"2013","journal-title":"Retrovirology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI97555","article-title":"Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells","volume":"128","author":"Huang","year":"2018","journal-title":"J Clin Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.immuni.2018.04.004","article-title":"Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4(+) T Cells","volume":"48","author":"Kuo","year":"2018","journal-title":"Immunity."},{"key":"B34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.chom.2017.03.008","article-title":"Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape","volume":"21","author":"Pollack","year":"2017","journal-title":"Cell Host Microbe."},{"key":"B35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2249.2005.02801.x","article-title":"Mammalian Toll-like receptors: to immunity and beyond","volume":"140","author":"Hopkins","year":"2005","journal-title":"Clin Exp Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature."},{"key":"B40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"aao4521","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e122673","DOI":"10.1172\/jci.insight.122673","article-title":"Dual TLR2 and TLR7 agonists as HIV latency-reversing agents","volume":"3","author":"Macedo","year":"2018","journal-title":"JCI Insight."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24 Week toll-like receptor 9 agonist treatment in HIV-1+ individuals: a single-arm, phase 1B\/2A trial","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS."},{"key":"B45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"II. Contribution to the Knowledge of Sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann Surg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e25238","DOI":"10.4161\/onci.25238","article-title":"Trial Watch: toll-like receptor agonists for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/jac\/dkr588","article-title":"Antiviral applications of Toll-like receptor agonists","volume":"67","author":"Horscroft","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrmicro2745","article-title":"Modulating immunity as a therapy for bacterial infections","volume":"10","author":"Hancock","year":"2012","journal-title":"Nat Rev Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/onci.20696","article-title":"Trial Watch: experimental Toll-like receptor agonists for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2013.00387","article-title":"Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases","volume":"4","author":"Savva","year":"2013","journal-title":"Front Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/onci.20931","article-title":"Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int Rev Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0960-9822(00)00700-4","article-title":"Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88","volume":"10","author":"Schnare","year":"2000","journal-title":"Curr Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J Leukoc Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from cell death to new life","volume":"6","author":"Venereau","year":"2015","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell."},{"key":"B58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"13766","DOI":"10.1073\/pnas.250476497","article-title":"The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors","volume":"97","author":"Ozinsky","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B60","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.immuni.2009.09.018","article-title":"Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer","volume":"31","author":"Kang","year":"2009","journal-title":"Immunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/intimm\/13.7.933","article-title":"Discrimination of bacterial lipoproteins by Toll-like receptor 6","volume":"13","author":"Takeuchi","year":"2001","journal-title":"Int Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.cell.2007.09.008","article-title":"Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide","volume":"130","author":"Jin","year":"2007","journal-title":"Cell."},{"key":"B63","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.4049\/jimmunol.163.12.6748","article-title":"The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors","volume":"163","author":"Means","year":"1999","journal-title":"J Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1206095","article-title":"The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota","volume":"332","author":"Round","year":"2011","journal-title":"Science."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1084\/jem.20021787","article-title":"Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2","volume":"197","author":"Gantner","year":"2003","journal-title":"J Exp Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science."},{"key":"B67","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1074\/jbc.274.16.10689","article-title":"Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction","volume":"274","author":"Chow","year":"1999","journal-title":"J Biol Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1084\/jem.189.11.1777","article-title":"MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4","volume":"189","author":"Shimazu","year":"1999","journal-title":"J Exp Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/35074106","article-title":"The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5","volume":"410","author":"Hayashi","year":"2001","journal-title":"Nature."},{"key":"B70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0167-4781(00)00289-X","article-title":"Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells","volume":"1518","author":"Chuang","year":"2001","journal-title":"Biochim Biophys Acta."},{"key":"B71","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.4049\/jimmunol.0901888","article-title":"Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling","volume":"184","author":"Guan","year":"2010","journal-title":"J Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"E4478","DOI":"10.1073\/pnas.1410293111","article-title":"Human TLR10 is an anti-inflammatory pattern-recognition receptor","volume":"111","author":"Oosting","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B73","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fimmu.2019.00482","article-title":"TLR10 senses HIV-1 proteins and significantly enhances HIV-1 infection","volume":"10","author":"Henrick","year":"2019","journal-title":"Front Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science."},{"key":"B77","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3389\/fimmu.2018.02874","article-title":"Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?","volume":"9","author":"Ho","year":"2018","journal-title":"Front Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1526250","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial Watch: toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/eji.200424955","article-title":"Toll-like receptor 6-independent signaling by diacylated lipopeptides","volume":"35","author":"Buwitt-Beckmann","year":"2005","journal-title":"Eur J Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.4049\/jimmunol.172.5.2739","article-title":"Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma","volume":"172","author":"Redecke","year":"2004","journal-title":"J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.1021\/jm201071e","article-title":"Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides","volume":"54","author":"Agnihotri","year":"2011","journal-title":"J Med Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"23755","DOI":"10.1074\/jbc.M110.116046","article-title":"Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening","volume":"285","author":"Guan","year":"2010","journal-title":"J Biol Chem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1400139","DOI":"10.1126\/sciadv.1400139","article-title":"Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists","volume":"1","author":"Cheng","year":"2015","journal-title":"Sci Adv."},{"key":"B85","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.1039\/C8CC06618C","article-title":"Structure-based discovery of a specific TLR1-TLR2 small molecule agonist from the ZINC drug library database","volume":"54","author":"Chen","year":"2018","journal-title":"Chem Commun."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1802042","DOI":"10.1002\/advs.201802042","article-title":"TLR1\/2 specific small-molecule agonist suppresses leukemia cancer cell growth by stimulating cytotoxic T lymphocytes","volume":"6","author":"Cen","year":"2019","journal-title":"Adv Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"14440","DOI":"10.1021\/jacs.8b09223","article-title":"Diprovocims: a new and exceptionally potent class of toll-like receptor agonists","volume":"140","author":"Morin","year":"2018","journal-title":"J Am Chem Soc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/jir.1989.9.445","article-title":"Production of interferon-alpha induced by dsRNA in human peripheral blood mononuclear cell cultures: role of priming by dsRNA-induced interferons-gamma and -beta","volume":"9","author":"Lepe-Zuniga","year":"1989","journal-title":"J Interferon Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1172\/JCI0215536","article-title":"Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination","volume":"110","author":"Wang","year":"2002","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-5-10","article-title":"Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models","volume":"5","author":"Zhu","year":"2007","journal-title":"J Transl Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-1-4615-1823-5_21","article-title":"Monophosphoryl lipid A as an adjuvant. Past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm Biotechnol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0960-894X(99)00374-1","article-title":"Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)","volume":"9","author":"Johnson","year":"1999","journal-title":"Bioorg Med Chem Lett."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1189\/jlb.0305172","article-title":"The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells","volume":"78","author":"Thompson","year":"2005","journal-title":"J Leukoc Biol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines."},{"key":"B95","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4155\/fmc-2017-0172","article-title":"Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives","volume":"10","author":"Zaffaroni","year":"2018","journal-title":"Future Med Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1126\/science.1154986","article-title":"An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models","volume":"320","author":"Burdelya","year":"2008","journal-title":"Science."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4049\/jimmunol.1003238","article-title":"A TLR5 agonist inhibits acute renal ischemic failure","volume":"187","author":"Fukuzawa","year":"2011","journal-title":"J Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","article-title":"Flagellin as an adjuvant: cellular mechanisms and potential","volume":"185","author":"Mizel","year":"2010","journal-title":"J Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1126\/science.1215584","article-title":"Structural basis of TLR5-flagellin recognition and signaling","volume":"335","author":"Yoon","year":"2012","journal-title":"Science."},{"key":"B100","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1073\/pnas.0631696100","article-title":"Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.4049\/jimmunol.181.4.2694","article-title":"Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5\/RIG-I-mediated differential signaling","volume":"181","author":"Kalali","year":"2008","journal-title":"J Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1006\/cimm.1999.1555","article-title":"Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848","volume":"197","author":"Ahonen","year":"1999","journal-title":"Cell Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/SHK.0b013e3181a5ac8a","article-title":"CL097, a TLR7\/8 ligand, inhibits TLR-4\u2013dependent activation of IRAK-M and BCL-3 expression","volume":"32","author":"Petricevic","year":"2009","journal-title":"Shock."},{"key":"B105","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4049\/jimmunol.1000060","article-title":"Generation of Th1-polarizing dendritic cells using the TLR7\/8 agonist CL075","volume":"185","author":"Spranger","year":"2010","journal-title":"J Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/0192-0561(92)90008-9","article-title":"in vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine)","volume":"14","author":"Pope","year":"1992","journal-title":"Int J Immunopharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-2036.2011.04745.x","article-title":"Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV","volume":"34","author":"Bergmann","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/15257770701490472","article-title":"Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine","volume":"26","author":"Xiang","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1073\/pnas.0813037106","article-title":"Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7","volume":"106","author":"Hayashi","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B110","doi-asserted-by":"publisher","first-page":"948540","DOI":"10.1155\/2015\/948540","article-title":"Synergistic stimulation with different TLR7 ligands modulates gene expression patterns in the human plasmacytoid dendritic cell line CAL-1","volume":"2015","author":"Hilbert","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e0146835","DOI":"10.1371\/journal.pone.0146835","article-title":"Molecular determinants of GS-9620-dependent TLR7 activation","volume":"11","author":"Rebbapragada","year":"2016","journal-title":"PLoS ONE."},{"key":"B112","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1016\/j.vaccine.2011.05.087","article-title":"Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine."},{"key":"B113","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1042\/BST0351461","article-title":"Synthetic agonists of Toll-like receptors 7, 8 and 9","volume":"35","author":"Agrawal","year":"2007","journal-title":"Biochem Soc Trans."},{"key":"B115","first-page":"553","article-title":"Technology evaluation: CpG-7909, Coley","volume":"5","author":"Paul","year":"2003","journal-title":"Curr Opin Mol Ther."},{"key":"B116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/135965350701200501","article-title":"Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist","volume":"12","author":"Vicari","year":"2007","journal-title":"Antivir Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sc USA."},{"key":"B118","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2014.12.002","article-title":"MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside","volume":"94","author":"Wittig","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.4049\/jimmunol.1602131","article-title":"Cutting edge: a Dual TLR2 and TLR7 ligand induces highly potent humoral and cell-mediated immune responses","volume":"198","author":"Gutjahr","year":"2017","journal-title":"J Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.molimm.2003.10.006","article-title":"TIR domain-containing adaptors define the specificity of TLR signaling","volume":"40","author":"Yamamoto","year":"2004","journal-title":"Mol Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"24192","DOI":"10.1074\/jbc.M109.023044","article-title":"MyD88 adapter-like (Mal)\/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses","volume":"284","author":"Verstak","year":"2009","journal-title":"J Biol Chem."},{"key":"B122","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature01182","article-title":"Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4","volume":"420","author":"Yamamoto","year":"2002","journal-title":"Nature."},{"key":"B123","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/gene.2011.21","article-title":"IRF7: activation, regulation, modification and function","volume":"12","author":"Ning","year":"2011","journal-title":"Genes Immun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science."},{"key":"B126","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/ni1569","article-title":"TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta","volume":"9","author":"Kagan","year":"2008","journal-title":"Nat Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ni986","article-title":"TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway","volume":"4","author":"Yamamoto","year":"2003","journal-title":"Nat Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature04369","article-title":"Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6","volume":"439","author":"Hacker","year":"2006","journal-title":"Nature."},{"key":"B129","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-2187-8-7","article-title":"TRAF molecules in cell signaling and in human diseases","volume":"8","author":"Xie","year":"2013","journal-title":"J Mol Signal."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/00002030-200009290-00002","article-title":"Concurrent infections and HIV pathogenesis","volume":"14","author":"Bentwich","year":"2000","journal-title":"AIDS."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/174.6.1191","article-title":"Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine","volume":"174","author":"Brichacek","year":"1996","journal-title":"J Infect Dis."},{"key":"B132","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/infdis\/174.2.401","article-title":"Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons","volume":"174","author":"Donovan","year":"1996","journal-title":"J Infect Dis."},{"key":"B133","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.157.3.1271","article-title":"Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation","volume":"157","author":"Goletti","year":"1996","journal-title":"J Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1086\/517297","article-title":"The impact of active herpes simplex virus infection on human immunodeficiency virus load","volume":"176","author":"Mole","year":"1997","journal-title":"J Infect Dis."},{"key":"B135","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood.V86.3.1082.1082","article-title":"Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1056\/NEJM199605093341903","article-title":"Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1","volume":"334","author":"Stanley","year":"1996","journal-title":"N Engl J Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1084\/jem.182.6.1727","article-title":"Activation of virus replication after vaccination of HIV-1-infected individuals","volume":"182","author":"Staprans","year":"1995","journal-title":"J Exp Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1086\/314491","article-title":"The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults","volume":"178","author":"Sulkowski","year":"1998","journal-title":"J Infect Dis."},{"key":"B139","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1365-2249.1999.00952.x","article-title":"Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes","volume":"117","author":"Toossi","year":"1999","journal-title":"Clin Exp Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1172\/JCI117924","article-title":"Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat","volume":"95","author":"Zhang","year":"1995","journal-title":"J Clin Invest."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1099\/0022-1317-79-6-1353","article-title":"Mycobacterium tuberculosis mannose-capped lipoarabinomannan can induce NF-kappaB-dependent activation of human immunodeficiency virus type 1 long terminal repeat in T cells","volume":"79","author":"Bernier","year":"1998","journal-title":"J Gen Virol."},{"key":"B142","first-page":"727","article-title":"Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus","volume":"7","author":"Lederman","year":"1994","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.4049\/jimmunol.166.4.2342","article-title":"Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4","volume":"166","author":"Equils","year":"2001","journal-title":"J Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1128\/CVI.00009-10","article-title":"HIV-1 reactivation induced by the periodontal pathogens Fusobacterium nucleatum and Porphyromonas gingivalis involves Toll-like receptor 2 [corrected] and 9 activation in monocytes\/macrophages","volume":"17","author":"Gonzalez","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1089\/aid.2007.0033","article-title":"Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation","volume":"23","author":"Nordone","year":"2007","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B146","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41564-018-0335-z","article-title":"HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy","volume":"4","author":"Ganor","year":"2019","journal-title":"Nat Microbiol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1196\/annals.1378.095","article-title":"Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells","volume":"1091","author":"Scheller","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"21897","DOI":"10.1074\/jbc.M311609200","article-title":"CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells","volume":"279","author":"Scheller","year":"2004","journal-title":"J Biol Chem."},{"key":"B150","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1128\/JVI.00222-16","article-title":"A novel toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J Virol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1074\/jbc.M111.327825","article-title":"Proline-proline-glutamic acid (PPE) protein Rv1168c of Mycobacterium tuberculosis augments transcription from HIV-1 long terminal repeat promoter","volume":"287","author":"Bhat","year":"2012","journal-title":"J Biol Chem."},{"key":"B152","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/aid.2018.0098","article-title":"Influence of biological sex, age and HIV status in an in vitro primary cell model of HIV latency using a CXCR4 tropic virus","volume":"34","author":"Macedo","year":"2018","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e0185162","DOI":"10.1371\/journal.pone.0185162","article-title":"Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro","volume":"12","author":"Larson","year":"2017","journal-title":"PLoS ONE."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.176.5.2888","article-title":"TLR7\/8 triggering exerts opposing effects in acute versus latent HIV infection","volume":"176","author":"Schlaepfer","year":"2006","journal-title":"J Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e02084","DOI":"10.1128\/JVI.02084-16","article-title":"Promising role of toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV","volume":"91","author":"Rochat","year":"2017","journal-title":"J Virol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/emboj\/cdg188","article-title":"HIV reproducibly establishes a latent infection after acute infection of T cells in vitro","volume":"22","author":"Jordan","year":"2003","journal-title":"EMBO J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.virol.2009.04.019","article-title":"TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells","volume":"389","author":"Thibault","year":"2009","journal-title":"Virology."},{"key":"B158","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cellsig.2015.11.005","article-title":"Toll-like receptor-3 mediates HIV-1 transactivation via NFkappaB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication","volume":"28","author":"Bhargavan","year":"2016","journal-title":"Cell Signal."},{"key":"B159","doi-asserted-by":"publisher","first-page":"e02166","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy","volume":"91","author":"Tsai","year":"2017","journal-title":"J Virol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12977-017-0335-8","article-title":"Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells","volume":"14","author":"Alvarez-Carbonell","year":"2017","journal-title":"Retrovirology."},{"key":"B161","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.4049\/jimmunol.172.7.4391","article-title":"Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells","volume":"172","author":"Sundstrom","year":"2004","journal-title":"J Immunol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1126\/science.3201255","article-title":"Development of disease and virus recovery in transgenic mice containing HIV proviral DNA","volume":"242","author":"Leonard","year":"1988","journal-title":"Science."},{"key":"B163","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.4049\/jimmunol.163.3.1506","article-title":"Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a Mac-1-positive host cell population","volume":"163","author":"Doherty","year":"1999","journal-title":"J Immunol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1084\/jem.183.4.1645","article-title":"Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo","volume":"183","author":"Gazzinelli","year":"1996","journal-title":"J Exp Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.4049\/jimmunol.170.10.5159","article-title":"Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication","volume":"170","author":"Equils","year":"2003","journal-title":"J Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4049\/jimmunol.171.3.1123","article-title":"Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2","volume":"171","author":"Bafica","year":"2003","journal-title":"J Immunol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1172\/JCI99005","article-title":"TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs","volume":"128","author":"Cheng","year":"2018","journal-title":"J Clin Invest."},{"key":"B168","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3389\/fimmu.2019.00725","article-title":"Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: a randomized double-blinded placebo controlled trial","volume":"10","author":"Saxena","year":"2019","journal-title":"Front Immunol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"127717","DOI":"10.1172\/jci.insight.127717","article-title":"TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia","volume":"4","author":"Del Prete","year":"2019","journal-title":"JCI Insight."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e62074","DOI":"10.1371\/journal.pone.0062074","article-title":"Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients","volume":"8","author":"Winckelmann","year":"2013","journal-title":"PLoS ONE."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology."},{"key":"B172","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antivir Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J Hepatol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/QAD.0b013e328339fe0b","article-title":"Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy","volume":"24","author":"Sogaard","year":"2010","journal-title":"AIDS."},{"key":"B175","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/mi.2017.59","article-title":"The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon","volume":"11","author":"Krarup","year":"2018","journal-title":"Mucosal Immunol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"e1005545","DOI":"10.1371\/journal.ppat.1005545","article-title":"A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes","volume":"12","author":"Jones","year":"2016","journal-title":"PLoS Pathog."},{"key":"B177","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxh025","article-title":"Polyriboinosinic polyribocytidylic acid [poly(I:C)]\/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes","volume":"16","author":"Fujimoto","year":"2004","journal-title":"Int Immunol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e01369","DOI":"10.1128\/AAC.01369-16","article-title":"TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells","volume":"61","author":"Bam","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B179","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.4049\/jimmunol.174.12.7676","article-title":"Immunization with HIV-1 Gag protein conjugated to a TLR7\/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses","volume":"174","author":"Wille-Reece","year":"2005","journal-title":"J Immunol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1371\/journal.pone.0001999","article-title":"Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7\/8 triggering","volume":"3","author":"Schlaepfer","year":"2008","journal-title":"PLoS ONE."},{"key":"B181","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.4049\/jimmunol.179.4.2097","article-title":"NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells","volume":"179","author":"Tomescu","year":"2007","journal-title":"J Immunol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.4049\/jimmunol.171.8.4320","article-title":"Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses","volume":"171","author":"Lore","year":"2003","journal-title":"J Immunol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e12771","DOI":"10.1111\/sji.12771","article-title":"Toll-like receptor polymorphism in host immune response to infectious diseases: a review","volume":"90","author":"Mukherjee","year":"2019","journal-title":"Scand J Immunol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/cei.12578","article-title":"Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases","volume":"180","author":"Skevaki","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.4049\/jimmunol.1303400","article-title":"X-Chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-alpha production of plasmacytoid dendritic cells from women","volume":"193","author":"Laffont","year":"2014","journal-title":"J Immunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nm.2004","article-title":"Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1","volume":"15","author":"Meier","year":"2009","journal-title":"Nat Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1097\/QAD.0b013e3282efb74b","article-title":"The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART","volume":"21","author":"Belmonte","year":"2007","journal-title":"AIDS."},{"key":"B188","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1128\/JVI.00674-16","article-title":"HIV DNA is frequently present within pathologic tissues evaluated at autopsy from combined antiretroviral therapy-treated patients with undetectable viral loads","volume":"90","author":"Lamers","year":"2016","journal-title":"J Virol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.chom.2016.02.018","article-title":"A Drug-Free Zone\u2013Lymph Nodes as a Safe Haven for HIV","volume":"19","author":"Licht","year":"2016","journal-title":"Cell Host Microbe."},{"key":"B190","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/aid.2017.0072","article-title":"Eradication of HIV from tissue reservoirs: challenges for the cure","volume":"34","author":"Rose","year":"2018","journal-title":"AIDS Res Hum Retroviruses."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/infdis\/jit308","article-title":"The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence","volume":"208","author":"Yukl","year":"2013","journal-title":"J Infect Dis."},{"key":"B192","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1128\/JVI.00895-12","article-title":"Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation","volume":"86","author":"McNamara","year":"2012","journal-title":"J Virol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-13-0484-2_8","article-title":"The molecular biology of HIV latency","volume":"1075","author":"Khoury","year":"2018","journal-title":"Adv Exp Med Biol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T14:00:21Z","timestamp":1695304821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":193,"alternative-id":["10.3389\/fimmu.2019.02450"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02450","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"article-number":"2450"}}